Demeetra AgBio, Inc.
- Biotech or pharma, therapeutic R&D
In 2021, Demeetra initiated a hemp gene editing program, which has since evolved into a broader focus on cannabinoid-derived therapeutics for fibrotic and inflammatory diseases.
Through a self-funded medicinal chemistry program, we have advanced two novel small molecule candidates to the IND-enabling stage. These compounds have demonstrated compelling preclinical efficacy in inflammatory bowel disease (IBD), including prevention of fibrostenotic strictures and promotion of mucosal healing.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}